NCT04520750View on ClinicalTrials.gov

VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita

PHASE3CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

June 30, 2021

Study Completion Date

December 15, 2022

Conditions
Pachyonychia Congenita
Interventions
DRUG

PTX-022

Safety and Efficacy of PTX-022 in the Treatment of Adults with Pachyonychia Congenita

Trial Locations (4)

55432

Minnesota Clinical Study Center, Fridley

84107

University of Utah, Murray

85053

Arizona Research Center, Phoenix

94304

Stanford University, Palo Alto

Sponsors
All Listed Sponsors
lead

Palvella Therapeutics, Inc.

INDUSTRY